CB₂: Therapeutic target-in-waiting

详细信息    查看全文

• 作者：Brady K. Atwood ; Alex Straiker ; Ken Mackie
• 关键词：CHO ; Chinese hamster ovary ; CNS ; central nervous system ; ERK ; extracellular-regulated kinase ; GPCR ; G protein-coupled receptor ; GRK ; G protein receptor kinase ; HEK ; human embryonic kidney ; JNK ; c-jun N terminal kinase ; MAP kinase ; mitogen-activated protei
• 刊名：Progress in Neuro-Psychopharmacology and Biological Psychiatry
• 出版年：2012
• 出版时间：2 July, 2012
• 年：2012
• 卷：38
• 期：1
• 页码：16-20
• 全文大小：208 K

文摘

CB₂ cannabinoid receptor agonists hold promise as a new class of therapeutics for indications as diverse as pain, neuroinflammation, immune suppression and osteoporosis. These potential indications are supported by strong preliminary data from multiple investigators using diverse preclinical models. However, clinical trials for CB₂ agonists, when they have been reported have generally been disappointing. This review considers possible explanations for the mismatch between promising preclinical data and disappointing clinical data. We propose that a more careful consideration of CB₂ receptor pharmacology may help move CB₂ agonists from ¡°promising¡± to ¡°effective¡± therapeutics.